8-K: Serina Therapeutics Presents Promising Data on Non-Immunogenic Lipid Nanoparticles at ACS Spring Meeting

Serina Therapeutics' Chief Development Officer presented data at the ACS Spring 2025 Meeting demonstrating that their POZ-lipid technology does not trigger an antibody response, unlike PEG-lipids commonly used in LNP formulations.

Summary

• Serina Therapeutics announced that its Chief Development Officer, Randall Moreadith, M.D., Ph.D., presented at the American Chemistry Society Spring 2025 Meeting and Expo.
• The presentation focused on Serina's proprietary POZ-lipid technology and its potential to improve the safety and efficacy of lipid nanoparticles (LNPs) for gene therapy and RNA-based medicines.
• Data presented showed that Serina's POZ-lipid did not trigger an IgM or IgG antibody response in rats after repeat dosing.
• In contrast, polyethylene glycol (PEG)-lipid standards, commonly used in current LNP formulations, elicited a strong and boosted antibody response.
• Anti-PEG antibodies have been implicated in anaphylaxis and other adverse events in humans receiving PEGylated mRNA vaccines.
• The absence of an immune response to Serina's POZ-lipid suggests it could enable the development of safer LNP formulations.

Sentiment

Score: 8

Explanation: The document presents promising data on Serina Therapeutics' POZ-lipid technology, suggesting a potential breakthrough in developing safer and more effective LNP formulations. The absence of an immune response to the POZ-lipid is a significant positive, and the company is actively working to advance its pipeline of drug product candidates.

Positives

• Serina's POZ-lipid technology demonstrates a non-immunogenic profile in rats, potentially mitigating the risk of adverse events associated with PEG-lipids.
• The POZ Platform has the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).
• Serina's LNP Laboratory has identified a PEOZ-lipid that is capable of replacing the PEG-lipid in standard LNP formulations.
• PEOZ-dma LNPs fail to elicit a detectable IgM or IgG immune response on repeat dosing.

Risks

• The forward-looking statements in the release are subject to risks and uncertainties, including those related to research and development, clinical trials, regulatory approvals, and competitive developments.
• The company's actual results may differ materially from those expressed or implied by the forward-looking statements.

Future Outlook

The company is focused on developing its POZ Platform technology and advancing its pipeline of drug product candidates to treat neurological diseases and other indications.

Management Comments

• Randall Moreadith, M.D., Ph.D., Chief Development Officer, presented new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA.
• His presentation, titled 'A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles,' highlighted findings on the immunogenic profile of Serina's proprietary POZ-lipid technology.

Industry Context

The development of non-immunogenic LNPs is a significant area of research in the biotechnology industry, driven by the need to improve the safety and efficacy of gene therapies and RNA-based medicines. The adverse events associated with PEG-lipids in mRNA vaccines have further highlighted the importance of finding alternative LNP formulations.

Comparison to Industry Standards

• The document references Pfizer and Moderna mRNA vaccines, which use PEG-lipids and have been associated with anaphylactic reactions.
• The document also mentions Onpattro, a PEG-dmg LNP, and its association with anti-PEG antibody development.
• Regado Bioscience's REG1 system is mentioned as an example of a PEGylated therapy that was halted due to serious adverse events related to anti-PEG antibodies.
• The document cites studies showing that Moderna's vaccine induced a much higher titer of both IgG and IgM post-boost than the Pfizer vaccination.

Stakeholder Impact

• Shareholders may benefit from the potential for increased value if the POZ-lipid technology proves successful.
• Patients could benefit from safer and more effective gene therapies and RNA-based medicines.
• The company's employees may benefit from the growth and success of the company.

Key Dates

Keywords

POZ Platform, Lipid Nanoparticles, LNP, Gene Delivery, Immunogenicity, PEG-lipid, POZ-lipid, Serina Therapeutics, Biotechnology